Selected highlights from the 27th San Antonio Breast Cancer Symposium

Bibliography

• BEATTIE MS, COSTANTINO JP, VOGEL Vet al.: Endogenous sex hormones and response to tamoxifen: an ancillary study in the breast cancer prevention trial (P-01). Breast Cancer Res. Treat. (2004) 88:S14 (Abstract 21).
   Google Scholar
• FISHER B, COSTANTINO JP, WICKERHAM DL et al.: Tamoxifen forprevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. NatL Cancer Inst. (1998) 90:1371-1387. First chemoprevention trial to show a reduction of breast cancer incidence.
   Google Scholar
• MARTINO S, CAULEY JA, BARRETT-CONNOR E, et aL: Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J. Natl. Cancer Inst. (2004) 96:1751–1761.
   PubMed Web of Science ®Google Scholar
• CAULEY JA, NORTON L, LIPPMAN ME et al.: Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res. Treat. (2001) 65:125–134.
   PubMed Web of Science ®Google Scholar
• BAUM M, BUZDAR A, CUZICK Jet ell.:Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer (2003) 98:1802-1810. First breast cancer adjuvant trial to show superiority of a new hormonal treatment over T.
   Google Scholar
• HOWELL A. CUZICK J, BAUM M et a/.:Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet (2005) 365:60–62.
   Google Scholar
• LOCKER GY ON BEHALF OF THE ATAC TRIALISTS' GROUP: Cost-utility analysis of anastrozole versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer from a US healthcare perspective. Breast Cancer Res. Treat. (2004) 88:S105 (Abstract 2085).
   Google Scholar
• JAKESZ R, KAUFMANN M, GNANT M et al: Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3,123 women enrolled in the ABCSG trial 8 and the ARNO 95 trial. Breast Cancer Res. Treat. (2004) 88:S7 (Abstract 2).
   Google Scholar
• COOMBES RC, HALL E, GIBSON LJ et al.: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl. J. Med. (2004) 350:1081–1092.
   PubMed Web of Science ®Google Scholar
• ••Largest breast cancer adjuvant trial to showthe benefit of switching to an Al after 2–3 years of T.
   Google Scholar
• COOMBES RC, HALL E, SNOWDON CF, BLISS JM: The Intergroup Exemestane Study: a randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen-updated survival analysis. Breast Cancer Res. Treat. (2004) 88:S7 (Abstract 3).
   Google Scholar
• GNANT M, JAKESZ R, MLINERITSCH B, LUSCHIN-EBENGREUTH G, SCHMID M, MENZEL C: Zoledronic acid effectively counteracts cancer treatment induced bone loss (CTIBL) in premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole versus goserelin plus tamoxifen - bone density subprotocol results of a randomized multicenter trial (ABCSG-12). Breast Cancer Res. Treat. (2004) 88:S8-S9 (Abstract 6).
   Google Scholar
• BRUFSKY A, HARKER G, BECK T, CARROLL R, TAN-CHIU E, SEIDLER C: Zoledronic acid (ZA) for prevention of cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (Let): preliminary results of the Z-FAST trial. Breast Cancer Res. Treat. (2004) 88:S233 (Abstract 6038).
   Google Scholar
• VAN DE VIJVER MJ, HE YD, VAN'T VEER LJ et al.: A gene-expression signature as a predictor of survival in breast cancer. N Engl. J. Med. (2002) 347:1999–2009.
   Google Scholar
• ••The first validation of a gene-expressionsignature obtained with microarray technology for the prediction of survival in breast cancer patients.
   Google Scholar
• PICCART MJ, LOI S, VAN'T VEER L et al.: Multi-center external validation of the Amsterdam 70-gene prognostic signature in node negative untreated breast cancer: are the results still outperforming the clinical-pathological criteria? Breast Cancer Res. Treat. (2004) 88 (Abstract 38).
   Google Scholar
• PAIK S, SHAK S, TANG G, KIM C et ell.: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl. J. Med. (2004) 351:2817–2826.
   Google Scholar
• •A study showing the routine applicability of microarray technology in the management of breast cancer patients.
   Google Scholar
• FISHER B, COSTANTINO J, REDMOND C et al: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl. J. Med. (1989) 320:479–484.
   PubMed Web of Science ®Google Scholar
• ••A pivotal study showing survival advantagefor ER-positive patients treated with T.
   Google Scholar
• FISHER B, DIGNAM J,WOLMARK N et al.: Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J. Natl Cancer Inst. (1997) 89:1673–1682.
   Google Scholar
• •A study showing the additive effect of chemotherapy over T in ER-positive breast cancer patients.
   Google Scholar
• ALBAIN K, BARLOW W, O'MALLEY F et al.: Concurrent (CAFT) versus sequetial (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: mature outcomes and new biologic correlates on Phase III intergroup trial 0100 (SWOG-8814). Breast Cancer Res. Treat. (2004) 88 (Abstract 37).
   Google Scholar
• BERRY DA, CIRRINCIONE C, HENDERSON IC et al.: Effects of improvements in chemotherapy on disease-free and overall survival of estrogen-receptor negative, node-positive breast cancer: 20-year experience of the CALGB & US Breast Intergroup. Breast Cancer Res. Treat. (2004) 88:S17 (Abstract 29).
   Google Scholar
• ROCHE H, FUMOLEAU P, SPEILMANN M et al.: Five years analysis of the PACS 01 trial: 6 cycles of FEC100 versus 3 cycles of docetaxel (D) for the adjuvant treatment of node positive breast cancer. Breast Cancer Res. Treat. (2004) 88:S16 (Abstract 27).
   Google Scholar
• MARTIN M, PIENKOWSKI T, MACKEY J et al.: TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001: 55 months follow-up. Breast Cancer Res. Treat. (2003) 82 (Abstract 43).
   Google Scholar
• LOESCH D, GRECO FA, O'SHAUGHNESSY J et al: A randomized, multicenter Phase III trial comparing regimens of doxorubicin + cyclophosphamide followed by paclitaxel or doxorubicin + paclitaxel followed by weekly paclitaxel as adjuvant therapy for patients with high risk breast cancer. Breast Cancer Res. Treat. (2004) 88:S16 (Abstract 28).
   Google Scholar
• CITRON M, BERRY D, CIRRINCIONE C et al.: Superiority of dose-dense (DD) over conventional scheduling (CS) and equivalence of sequential (SC) versus combination adjuvant chemotherapy (CC) for node-positive breast cancer (CALGB 9741; INT C9741). Breast Cancer Res. Treat. (2002) 76:S32 (Abstract 15).
   Google Scholar
• •The first convincing demonstration of the beneficial effect of the dose-dense approach of adjuvant chemotherapy for breast cancer.
   Google Scholar
• BEAR HD, ANDERSON S, SMITH RE et al.: A randomized trial comparing preoperative (preop) doxorubicin/ cyclophosphamide (AC) to preop AC followed by preop docetaxel (T) and to preop AC followed by postoperative (postop) T in patients (pts) with operable carcinoma of the breast: results of NSABP B-27. Breast Cancer Res. Treat. (2004) 88:S26 (Abstract 26).
   Google Scholar
• BUZDAR AU, HUNT K, SMITH T et ell.:Significantly higher pathological complete remission rate following neoadjuvant therapy with trastuzumab, paclitaxel, and anthracycline-containing chemotherapy: initial results of a randomized trial in operable breast cancer with HER2 positive disease. Proc. Am. Soc. Clin. Oncol (2004) 23:7 (Abstract 520).
   Google Scholar
• •A study demonstrating the benefit of neoadjuvant trastuzumab in HER-2-positive patients in terms of pCR.
   Google Scholar
• COUDERT B, ARNOULD L, MOREAU Let al.: Final pathological complete response (pCR) of neoadjuvant (NA) trastuzumab (T) and docetaxel (D) chemotherapy (CT) in HER-2 positive (3+) localized breast cancer without possible primary conserving surgery. Breast Cancer Res. Treat. (2004) 88:S107 (Abstract 2092).
   Google Scholar
• OVERMOYER B, SILVERMAN P, LEEMING R et al.: Phase II trial of neoadjuvant docetaxel with or without bevacizumab in patients with locally advanced breast cancer. Breast Cancer Res. Treat. (2004) 88:S106 (Abstract 2088).
   Google Scholar
• ROBERTSON JF, GUTTERIDGE E, CHEUNG KL, PINDER S, WAKELING A: Clinical efficacy of fitlyestrant and effects on estrogen receptor levels during first-line endocrine treatment of patients with advanced breast cancer. Breast Cancer Res. Treat. (2004) 88:S236-7 (Abstract 6049).
   Google Scholar
• PEREY L, PARIDAENS R, NOLE. F et al.: Fulvestrant (Faslodex114) as hormonal treatment in postmenopausal patients with advanced breast cancer (ABC) progressing after treatment with tamoxifen and aromatase inhibitors: update of a Phase II SAKK trial. Breast Cancer Res. Treat. (2004) 88:S236 (Abstract 6048).
   Google Scholar
• INGLE JN, ROWLAND KM, SUMAN VJ et al.: Evaluation of fitlyestrant in women with advanced breast cancer and progression on prior aromatase inhibitor therapy: a Phase II trial of the North Central Cancer Treatment Group. Breast Cancer Res. Treat. (2004) 88:S38 (Abstract 409).
   Google Scholar
• BASELGA J, CARBONELL X, CASTANEDA-SOTO NJ et al.: Updated efficacy and safety analyses of 3-weekly Herceptin® monotherapy in women with HER2-positive metastatic breast cancer: results from twelve months of follow-up to a Phase II study. Breast Cancer Res. Treat. (2004) 88:S126 (Abstract 3042).
   Google Scholar
• VOGEL CL, COBLEIGH MA, TRIPATHY D et al.: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. (2002) 20:719–726.
   PubMed Web of Science ®Google Scholar
• •A study confirming the efficacy of trastuzumab in HER-2-positive metastatic breast cancer patients.
   Google Scholar
• SLAMON DJ, LEYLAND-JONES B, SHAK S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N EngL J. Med. (2001) 344:783–792.
   PubMed Web of Science ®Google Scholar
• ••A study suggesting that trastuzumab pluschemotherapy may be the first treatment of choice in HER-2-positive metatstatic breast cancer patients.
   Google Scholar
• WOLFF AC, WANG M, SPARANO JA, PINS MR, THOR AD, DAVIDSON NE: Cardiac safety and clinical activity of pegylated liposomal doxorubicin (D) and docetaxel (T) with and without trastuzumab (H) as 1st line chemotherapy in HER2-positive and HER2-negative metastatic breast cancer (MBC): Eastern Cooperative Oncology Group (ECOG) trial E3198. Breast Cancer Res. Treat. (2004) 88:S125 (Abstract 3040).
   Google Scholar
• CORTES J, CLIMENT M, LLUCH A et al.: Updated results of a Phase II study (M77035) of Myocet® combined with weekly Herceptin® and paclitaxel in patients (pts) with HER2-positive locally advanced or metastatic breast cancer (LABC/MBC). Breast Cancer Res. Treat. (2004) 88:S125-S126 (Abstract 3041).
   Google Scholar
• BRUFSKY A, ORLANDO M, FOX K et al.: Phase II study of gemcitabine (Gem) and trastuzumab (T) combination therapy in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC). First stage results. Breast Cancer Res. Treat. (2004) 88:S128 (Abstract 3047).
   Google Scholar
• XU L, SONG S, ZHU J et al.: Results of a Phase II trial of Herceptin® plus Xeloda® in patients with previously untreated HER2-positive metastatic breast cancer. Breast Cancer Res. Treat. (2004) 88:S128 (Abstract 3049).
   Google Scholar
• ARPINO G, WEISS H, WAKELING AE, OSBORNE K, SCHIFF R: Complete disappearance of ER+/HER2+ breast cancer xenografts with the combination of gefitinib, trastuzumab, and pertuzumab to block HER2 cross-talk with ER and restore tamoxifen inhibition. Breast Cancer Res. Treat. (2004) 88:S15 (Abstract 23).
   Google Scholar
• ARTEAGA CL, O'NEIL A, MOULDER SL et ell.: ECOG1100: a Phase I-II study of combined blockade of the erbB receptor network with trastuzmab and gefitinib (Iressa') in patients (pts) with HER2-overexpressing metastatic breast cancer. Breast Cancer Res. Treat. (2004) 88:S15-S16 (Abstract 25).
   Google Scholar
• BURRIS HA 3rd, STORNIOLO AM, OVERMOYER EA et al.: A Phase I, open-label study of the safety, tolerability and pharmacokinetics oflapatinib (GW572016) in combination with trastuzumab. Breast Cancer Res. Treat. (2004) 88:S126 (Abstract 3043).
   Google Scholar
• PEGRAM MD, YEON C, KU NC, GAUDREAULT J, SLAMON DJ: Phase I combined biological therapy of breast cancer using two humanized monoclonal antibodies directed against HER2 proto-oncogene and vascular endothelial growth factor (VEGF). Breast Cancer Res. Treat. (2004) 88:S124-S125 (Abstract 3039).
   Google Scholar
• BOCCARDO F, RUBAGOTTI A, AMOROSO D et al.: Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. Breast Cancer Res. Treat. (2003) 82:S6–S7.
   Google Scholar
• •First report of a beneficial effect of the switch to an AIs after 2–3 years of adjuvant T.
   Google Scholar
• MONTEMURRO F, VALABREGA G, AGLIETTA M: Trastuzumab-based combination therapy for breast cancer. Expert. Opin. Pharmacother. (2004) 5:81–96.
   PubMed Web of Science ®Google Scholar
• JASSEM J, PLUZANSKA A, PIENKOWSKI T et al.: A randomized Phase III multicenter trial of doxorubicin and paclitaxel (AT) versus fluorouracil-doxorubicin-cyclophosphamide (FAC) as first-line therapy metastatic breast cancer (MBC): long-term efficacy and external review of results. Breast Cancer Res. Treat. (2004) 88:S198 (Abstract 5043).
   Google Scholar
• BLOHMER J-U, HAUSCHILD M, HILFRICH J, KLEINE-TEBBE A, LICHTENEGGER W: Safety and efficacy of first-line epirubicin-docetaxel versus epirubicin-cyclophosphamide: updated results of a multicenter randomized Phase III trial in metastatic breast cancer. Breast Cancer Res. Treat. (2004) 88:S199 (Abstract 5045).
   Google Scholar